In 2024, Daniel O'Day earned $21.90M in total compensation at Gilead Sciences, including $1.77M salary and $18.79M in stock. Most recently acquired 224,504 shares in Feb 2025. Currently holds stock worth $69.93M. 6+ years at the helm of Gilead Sciences.
Compensation History
Annual executive compensation data for Daniel O'Day, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$21.90M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Salary
$1.77MBoard Justification
Our executive compensation program is designed through thoughtful application of a combination of pay elements to promote an adept, driven executive team whose incentives align with Gilead’s and stockholder interests.
Bonus
$0.00Board Justification
N/A
Other Compensation
$1.34MBoard Justification
Includes the 2024 value of perquisites and other personal benefits, company contributions to our Section 401(k) plan, and term life insurance premiums. $1,311,784, which includes (i) a final $750,000 of company contribution credited to Mr. O’Day’s deferred compensation plan account on March 1, 2024. These contributions were provided to compensate him for the forfeiture of his pension benefits with his former employer; (ii) $35,517 reflecting the aggregate incremental cost incurred by us for Mr. O’Day’s personal use of our corporate automobiles; (iii) $240,998 reflecting the aggregate incremental cost incurred by us for the personal use of our corporate aircraft; and (iv) $285,269 reflecting the aggregate incremental cost incurred by us for security services provided to Mr. O’Day.
Restricted Stock
Board Justification
Shares acquired upon vesting of RSUs and/or performance shares
Performance Metrics
Net Product Revenue, Relative TSR, Non-GAAP Operating Income
Daniel O'Day
CEO of Gilead Sciences
Education
B.S. degree in biology from Georgetown University, M.B.A. from Columbia Business School
Field of Expertise
Healthcare & Life Sciences - Pharmaceuticals
Sector of Economy
Healthcare
Born
November 30, 1964 - 61 years ago
CEO of Gilead Sciences for
6 years 9 months (Mar 2019 - Present)
Previous Experience
CEO of Roche Pharmaceuticals
Other Gilead Sciences CEOs
Holdings
Track Daniel O'Day's stock holdings and portfolio value over time.
Insider Trading
Daniel O'Day's recent stock transactions, purchases, and sales filed with the SEC.
224,504 shares
GILD
Feb 4, 2025
Received
230,747 shares
GILD
Jan 31, 2024
Received
215,017 shares
GILD
Jan 24, 2023
Received
146,678 shares
GILD
Jan 26, 2022
Received
59,100 shares
GILD
Jan 26, 2021
Received
19,204 shares
GILD
Jan 29, 2020
Received
Rivals
Compare Daniel O'Day with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Reshma Kewalramani
CEO of Vertex Pharmaceuticals
2022 Compensation
Stock
$10.64M
Salary
$1.40M
Bonus
$3.78M
Other
$43.06K
Total Holdings
$50.74M
Marianne De Backer, MSc, Ph.D., MBA
CEO of Vir Biotechnology, Inc.
2023 Compensation
Stock
$5.80M
Salary
$675.00K
Bonus
$855.36K
Other
$437.18K
Total Holdings
$556.68K
John L. Higgins
CEO of Ligand Pharmaceuticals
2022 Compensation
Stock
$0.00
Salary
$730.46K
Bonus
$0.00
Other
$0.00
Total Holdings
$5.64M